Aims/hypothesis Monocyte chemoattractant protein-1 (MCP-1)/chemokine (C-C motif) ligand (CCL) 2 (CCL2) secreted from white adipose tissue (WAT) in obesity has been reported to contribute to tissue macrophage accumulation and insulin resistance by inducing a chronic inflammatory state. MCP-1 has been shown to be elevated in the fatty liver of lipoatrophic A-ZIP-transgenic (A-ZIP-Tg) mice. Treatment of these mice with the CC chemokine receptor (CCR) 2 antagonist has been shown to ameliorate the hyperglycaemia, hyperinsulinaemia and hepatomegaly, in conjunction with reducing liver inflammation. However, since CCR2 antagonists can block not only MCP-1 but also MCP-2 (CCL8) and MCP-3 (CCL7), it remains unclear whether MCP-1 secreted from the liver could contribute to hyperglycaemia, hyperinsulinaemia and hepatomegaly in conjunction with liver inflammation, as well as to the M1 and M2 states of macrophage polarisation. Methods To address these issues, we analysed the effects of targeted disruption of MCP-1 in A-ZIP-Tg mice. Results MCP-1 deficiency alone or per se resulted in a significant amelioration of insulin resistance in A-ZIP-Tg mice, which was associated with a suppression of extracellular signal-regulated protein kinase (ERK)-1/2 and p38 mitogen-activated protein kinase (p38MAPK) phosphorylation in liver. Although MCP-1 deficiency did not reduce the expression of macrophage markers, it increased the expression of the genes encoding M2 macrophage markers such as Arg1 and Chi3l3, as well as significantly reducing the triacylglycerol content of livers from A-ZIP-Tg mice. Conclusions/ interpretation Our data clearly indicated that MCP-1 deficiency improved insulin resistance and hepatic steatosis in A-ZIP-Tg mice and was associated with switching macrophage polarisation and suppressing ERK-1/2 and p38MAPK phosphorylation.
Introduction
Obesity is associated with increased infiltration of macrophages into the adipose tissues. These adipose tissue macrophages (ATMs) are currently considered to be a major cause of obesity-associated chronic low-grade inflammation via the secretion of a wide variety of inflammatory molecules [1, 2] , including TNF-α, IL-6 [3] and monocyte chemoattractant protein-1 (MCP-1). These inflammatory molecules may have local effects on white adipose tissue (WAT) physiology as well as potential systemic effects on other organs that culminate in insulin resistance.
Among the inflammatory molecules upregulated in the adipose tissues of obese animals and humans, MCP-1 is a member of the cysteine-cysteine (C-C) chemokine family and promotes the migration of inflammatory cells by chemotaxis and integrin activation [4] . Both Mcp-1 (also known as Ccl2) mRNA expression in WAT and plasma MCP-1 levels have been found to correlate positively with the degree of obesity in the individual [5] . In addition, increased production of MCP-1 in WAT precedes the production of other macrophage markers during the development of obesity [6] . Mice overproducing MCP-1 in adipocytes showed macrophage recruitment in WAT and exhibited insulin resistance in the skeletal muscles (SKM) and liver [7] . Regarding the mechanisms, it was reported that MCP-1 stimulates the phosphorylation of extracellular signal-regulated protein kinase (ERK) through the C-C chemokine receptor (CCR) 2 [8] and activation of ERK-1/2 induces insulin resistance via decreased tyrosine phosphorylation of insulin receptor beta (IR-β) [7] as well as increased serine phosphorylation of IRS-1 [9] .
Macrophage activation has been operationally defined across two separate polarisation states: M1 and M2. M1, or 'classically activated', macrophages are induced by proinflammatory mediators such as lipopolysaccharide, whereas M2, or 'alternatively activated', macrophages generate high levels of anti-inflammatory cytokines such as IL-10, arginase-1(Arg1), chitinase 3-like 3 (Chi3l3) and TGF-β [10] . It was previously reported that disruption of MCP-1, or its receptor CCR2, in obese mice resulted in decreased macrophage infiltration in WAT and improved metabolic function [11, 12] . Moreover, ATMs from obese Ccr2-deficient mice produce M2 markers at levels similar to those seen in lean mice [12] . These data suggest that the MCP-1/ CCR2 axis contributes to macrophage polarisation. Therefore, the phenotypic switch in ATM polarisation is thought to lead to amelioration of insulin resistance.
In contrast to obesity, lipoatrophic diabetes is caused by a deficiency of WAT and is characterised by severe hepatic steatosis and insulin resistance. Moitra and colleagues have generated lipoatrophic A-ZIP transgenic (A-ZIP-Tg) mice, which are profoundly insulin resistant and hyperlipidaemic [13] [14] [15] . In addition, these mice exhibit severe hepatic steatosis and at the same time a chronic state of inflammation as indicated by high systemic levels of inflammatory cytokines such as IL-1β, IL-6, IL-12 and MCP-1 [16] [17] [18] . At the very least, MCP-1 is most abundantly expressed in the liver from A-ZIP-Tg mice [18] . Moreover, treatment of the lipoatrophic A-ZIP-Tg mice with a CCR2 antagonist has been shown to ameliorate the hyperglycaemia, hyperinsulinaemia and hepatomegaly, in conjunction with reducing liver inflammation. However, since CCR2 antagonist can block not only MCP-1, but also MCP-2 (chemokine [C-C motif] ligand [CCL] 8) and MCP-3 (also known as CCL7), it remains unclear whether MCP-1 secreted from liver could contribute to hyperglycaemia, hyperinsulinaemia and hepatomegaly in conjunction with liver inflammation, as well as to M1/M2 polarisation.
In this study, we hypothesised that MCP-1 secreted from the liver might also play an important role in the regulation of macrophage polarisation and insulin resistance-causing kinases such as ERK and p38 mitogen-activated protein kinase (p38MAPK) in liver. To address these issues, we analysed the effects of a targeted disruption of MCP-1 in lipoatrophic A-ZIP-Tg mice. We showed for the first time that a targeted disruption of MCP-1 alone in lipoatrophic diabetic A-ZIP-Tg mice resulted in decreased ERK-1/2 and p38MAPK phosphorylation and increased alternative M2 activation of macrophages, with at the same time an amelioration of insulin resistance and hepatic steatosis.
Methods

Generation of A-ZIP-Tg×Mcp1
−/− mice A-ZIP/F-1 (A-ZIPTg) mice were generous gifts from C. Vinson of the National Cancer Institute at Frederick, MD, USA. Mcp1 −/− mice were purchased from the Jackson Laboratory (Bar Harbor, ME, USA) and C57BL/6 mice from CLEA Japan (Fujinomiya, Shizuoka, Japan). A-ZIP/F-1 mice were on an FVB/N (FVB) background. MCP-1 homozygous-knockout mice were on a C57BL/6 background, which had been backcrossed to C57BL/6 mice for 10 generations.
To generate A-ZIP-Tg Mcp1 +/− mice, conceptuses that were obtained by in vitro fertilisation of ova from Mcp1 −/− mice and sperm from A-ZIP-Tg mice were implanted into pseudo-pregnant foster mothers as previously described [19] . Fig. 2a ) was similar to that of A-ZIP-Tg female mice (Fig. 1a) . MCP-1 deficiency significantly ameliorated hyperglycaemia (ESM Fig. 2b ) but not hyperinsulinaemia in A-ZIP-Tg male mice (ESM Fig. 2c ). These data suggested that the insulin-sensitive phenotype of A-ZIP-TgMcp1 −/− mice was prominent in female mice compared with male mice. We thus used female mice in this study.
Mice Mice were housed in cages and maintained on a 12-h light/dark cycle. For all experiments, the diet was standard chow (CE-2; CLEA Japan) with the following composition: 25.6% (wt/wt) protein, 3.8% fibre, 6.9% ash, 50.5% carbohydrates, 4% fat and 9.2% water [19] [20] [21] . The animal care and use procedures were approved by the Animal Care Committee of the University of Tokyo.
Northern blot analysis Northern blotting was carried out according to the method described previously [20, 21] . Total RNA was extracted from various tissues with TRIzol reagent according to the manufacturer's instructions (Invitrogen, Carlsbad, CA, USA). Total RNA (15 μg) was loaded onto a 1.3% agarose gel and transferred to a nylon membrane (Hybond N+; GE Healthcare Life Sciences, Hino, Tokyo, Japan). MCP-1 coding sequence cDNA was used as the probe template. The cDNA probe template of MCP-1 was prepared by RT-PCR using specific primers. The forward primer was 5′-CCATGCAGGTCCCTGTC-3′ and the reverse primer was 5′-CTAGTTCACTGTCACAC-3′, as previously described [7] . The corresponding bands were quantified by exposure of BAS2000 to the filters and measurement with BAStation software (Fuji Film, Minato-ku, Tokyo, Japan). The primer sets and the probe for mouse cyclophilin were as follows: the forward primer was 5′-GGTCCT GGCATCTTGTCCAT-3′, the reverse primer was 5′-CAGTCTTGGCAGTGCAGATAAAA-3′; and the probe was 5′-CTGGACCAAACACAAACGGTTCCCA-3′. The relative amount of each transcript was normalised to the amount of mouse cyclophilin mRNA.
Real-time quantitative PCR
Blood sample assays and in vivo glucose homeostasis Glucose tolerance tests (GTTs) were conducted as previously described with slight modifications [20, 21] . For the GTTs, mice were deprived of food for 6 h and then orally administered with D-glucose (1.5 g per kg body weight). Plasma glucose and plasma triglycerol (TG) levels in the fed state were determined using a glucose B-test and TG E-type test (Wako Pure Chemical Industries, Yodogawa-ku, Osaka, Japan), respectively. Plasma insulin levels were measured with an insulin immunoassay (Shibayagi, Shibukawa, Gunma, Japan). Plasma MCP-1 levels in the fed state were measured using a mouse immunoassay kit (Pierce Biotechnology, Rockford, IL, USA).
Antibodies Mouse monoclonal anti-phosphotyrosine antibody 4G10 (αPY) was purchased from Merck Millipore (Billerica, MA, USA). Rabbit polyclonal antibody to IR-β was purchased from Santa Cruz Biotechnology (Santa Cruz, CA, USA). Rabbit polyclonal antibodies against ERK-1/2, phospho-ERK-1/2 (Thr202/Tyr204), p38MAPK, phosphor-p38MAPK (Thr180/ Tyr182), Akt and phospho-Akt (Ser-473) were purchased from Cell Signaling Technology (Danvers, MA, USA).
Immunoblotting and immunoprecipitation
Immunoblotting and immunoprecipitation were conducted as previously described [22] . In brief, in the fed state, the skeletal muscles from the hind limbs or livers were removed. The samples were homogenised in ice-cold 1% Nonidet P-40-buffer (25 mmol/l Tris-HCl [pH 7.4], 10 mmol/l sodium orthovanadate, 10 mmol/l EGTA and 1 mmol/l phenylmethylsulfonyl fluoride) and centrifuged. For immunoblotting, muscle homogenates containing 5 mg of total protein or liver homogenates containing 15 mg of total protein were incubated with the indicated primary antibodies and horseradish peroxidase-conjugated anti-mouse-IgG secondary antibody and were detected with enhanced chemiluminescence (ECL) reagent (GE Healthcare Life Sciences). For immunoprecipitation, muscle homogenates containing 5 mg of total protein or liver homogenates containing 15 mg of total protein were also incubated with the indicated antibodies followed by addition of protein GSepharose. The immunoprecipitates were washed with 1% Nonidet P-40-buffer three times. The immunoprecipitates were subjected to immunoblotting with the indicated primary antibodies and horseradish peroxidase-conjugated anti-mouse-IgG secondary antibody and were detected with ECL reagent.
Histological analyses and TG content in liver Livers from WT mice, A-ZIP-Tg mice and A-ZIP-Tg×Mcp1
−/− mice were fixed overnight in 10% formalin (vol./vol.). Samples were routinely embedded in paraffin. Approximately 5 μm-thick slices obtained from these liver samples were stained with haematoxylin and eosin. The liver homogenates were extracted and their TG content was determined as previously described [19] .
Statistical analysis Results are expressed as means±SEM. The Student's t test was performed to compare two groups. Data involving more than two groups were assessed by ANOVA. Values of p<0.05 were considered statistically significant. For details of the hyperinsulinaemic-euglycaemic clamp study and antibodies used in immunoprecipitation and immunoblotting, please refer to the ESM Methods.
Results
Plasma MCP-1 concentration and Mcp-1 mRNA expression in fatty liver were increased in lipoatrophic A-ZIP-Tg mice Many previous studies have reported elevated plasma MCP-1 concentration and Mcp-1 mRNA expression in WAT of obese and diabetic mice [7, 11, [23] [24] [25] . As reported [18] , plasma MCP-1 concentrations were significantly elevated in A-ZIPTg mice compared with WT mice (Fig. 1a) . A previous study showed that, in WT mice, Mcp-1 mRNA was not detected in any tissues [11] , whereas in A-ZIP-Tg mice, as previously reported [18] , Mcp-1 mRNA was most abundantly expressed in the liver among all the tissues we examined, including brown adipose tissue (BAT), except for WAT, because lipoatrophic A-ZIP-Tg mice still have BAT but not WAT, as reported in other studies [12] [13] [14] 18] (Fig. 1b) . It has been reported that MCP-1 is abundantly expressed in Kupffer cells, as well as in hepatocytes in the liver [26, 27] MCP-1 deficiency decreased body weight gain and liver weight in A-ZIP-Tg mice To clarify the pathophysiological roles of elevated MCP-1 levels in lipoatrophic A-ZIP-Tg mice, we generated A-ZIP-Tg×Mcp1 −/− mice. MCP-1 deficiency in A-ZIP-Tg mice resulted in decreased body weight compared with A-ZIP-Tg mice (Fig. 2a) , although the food intake of A-ZIP-Tg×Mcp1 −/− mice was not significantly different from that seen in A-ZIP-Tg mice (ESM Table 1 ). Furthermore, the liver weight of A-ZIP-Tg×Mcp1 −/− mice was decreased compared with that of A-ZIP-Tg mice (Fig. 2b) .
MCP-1 deficiency ameliorated glucose tolerance in lipoatrophic A-ZIP-Tg mice A-ZIP-Tg×Mcp1 −/− mice showed amelioration of hyperglycaemia, hyperinsulinaemia and hypertriacylglycerolaemia compared with A-ZIP-Tg mice (Fig. 3a-c) . To further clarify the effects of MCP-1 deficiency in A-ZIP-Tg mice on glucose tolerance and insulin sensitivity, we performed GTTs. Plasma glucose levels and plasma insulin levels during the GTTs were significantly lower in A-ZIP-Tg×Mcp1 −/− mice than in A-ZIP-Tg mice (Fig. 3d,e) , suggesting that MCP-1 deficiency in A-ZIP-Tg mice partially ameliorated glucose intolerance. In WT mice, plasma insulin levels were increased after glucose administration, whereas they were remarkably decreased in A-ZIPTg and A-ZIP-Tg-Mcp1 −/− mice, consistent with previous observations that prolonged hyperinsulinaemia due to severe insulin resistance can result in decreased glucosestimulated insulin-secretion, in particular decreased earlyphase insulin secretion [28] . A hyperinsulinaemiceuglycaemic clamp study revealed that the glucose infusion rate was significantly increased in A-ZIP-Tg-Mcp1 −/− mice compared with A-ZIP-Tg mice (ESM Fig. 3 ), indicating that disruption of MCP-1 in A-ZIP-Tg mice could ameliorate insulin resistance.
Livers from A-ZIP-Tg×Mcp1
−/− mice showed increased markers of alternatively activated M2 macrophages Many studies have demonstrated that macrophage infiltration and levels of proinflammatory cytokines such as MCP-1 and TNF-α are increased in WAT of human obese individuals and several models of rodent obesity [29, 30] . We examined whether the expression of macrophage marker genes would be elevated in other tissues than WAT, such as liver, SKM and BAT, in A-ZIP-Tg mice. The mRNA expressions of Mcp-1, Mcp-3 (Ccl7), Ccr2, Emr1 (EGF-like module containing, mucin-like, hormone receptor-like 1) and Cd68 (CD68 antigen) were increased in the liver (Fig. 4a- Because a previous report showed that ATMs isolated from obese Ccr2-deficient mice expressed alternatively activated M2-macrophage markers [12] , we hypothesised that livers from A-ZIP-Tg×Mcp1 −/− mice might contain M2-polarised macrophages more abundantly. Interestingly, characteristic M2-macrophage marker genes such as Chi3l3, Arg1 and Tgfb1 were significantly increased in livers from A-ZIPTg×Mcp1 −/− mice ( Fig. 4f-h ). In contrast to liver, characteristic M2-macrophage marker genes such as Chi3l3, Arg1 and Tgfb1 were not significantly changed in SKM and BAT from A-ZIP-Tg×Mcp1 −/− mice (ESM Fig. 7) . Thus, MCP-1 deficiency did not reduce macrophage markers but rather induced macrophages to shift to a M2-polarised state in livers from A-ZIP-Tg mice. These data suggest that MCP-1 deficiency enhances M2 polarisation in livers of A-ZIP-Tg mice.
MCP-1 deficiency decreased liver TG content in A-ZIP-Tg mice It was previously reported that A-ZIP-Tg mice showed dyslipidaemia and severe hepatic steatosis [13] . Liver weights were markedly reduced in A-ZIP-Tg×Mcp1 −/− mice compared with A-ZIP-Tg mice (Fig. 2b) . Representative histological sections of livers showed that MCP-1 deficiency decreased TG accumulation (Fig. 5a ). We subsequently determined that the TG content in livers from A-ZIP-Tg×Mcp1
−/− mice was significantly less than that in livers from A-ZIP-Tg mice (Fig. 5b) . To clarify the mechanism by which hepatic steatosis was improved, we studied the expression of genes involved in lipid and energy metabolism and found that expression of Ppara mRNA tended to be increased and expression of genes involved in energy dissipation such as Ucp2 significantly increased in A-ZIP-Tg-Mcp1 −/− mice compared with A-ZIP-Tg mice, whereas the expression of genes involved in lipogenesis such as Srebp-1c (Srebf1) and Scd-1 was not significantly changed (ESM Fig. 8 ). −/− mice, n016. **p<0.01 vs A-ZIP-Tg mice MCP-1 deficiency enhanced insulin signalling in livers of A-ZIP-Tg mice Previous studies have reported that MCP-1 induces phosphorylation of ERK through activation of CCR2 in SKM, myocytes, kidney and leukaemia cells [7, 8, 31, 32] . Moreover, Bost et al reported that mice lacking ERK-1 were protected from high-fat diet-induced obesity and insulin resistance [33] . Thus, we hypothesised that inhibition of ERK signalling would improve insulin signalling in A-ZIP-Tg mice, so we studied phosphorylation of ERK-1/2 in livers from A-ZIP-Tg mice and A-ZIPTg×Mcp1 −/− mice. In fact, ERK-1/2 and p38MAPK phosphorylation were significantly increased in livers from A-ZIP-Tg mice compared with WT mice. Conversely, phosphorylation of ERK-1/2 was decreased in livers from A-ZIP-Tg×Mcp1 −/− mice compared with A-ZIP-Tg mice (Fig. 6a) . We next examined the effects of MCP-1 deficiency on insulin signalling in livers from A-ZIP-Tg mice.
A-ZIP Tg
In livers from A-ZIP-Tg×Mcp1 −/− mice, tyrosine phosphorylation of IR-β and serine phosphorylation of Akt were significantly increased compared with that seen in A-ZIP-Tg mice (Fig. 7) . Moreover, Ser 612 in IRS-1 has been reported to be phosphorylated by ERK [33] , which would result in inhibition of insulin signalling. The amount of Ser 612 phosphorylation in IRS-1 was significantly decreased in livers from A-ZIP-Tg×Mcp1 −/− mice compared with A-ZIP-Tg mice (ESM Fig. 9 ). Furthermore, in SKM from A-ZIP-Tg×Mcp1 −/− mice, tyrosine phosphorylation of IR-β was significantly, and serine phosphorylation of Akt tended to be, increased compared with A-ZIP-Tg mice (ESM Fig. 10 ).
Discussion
MCP-1/CCL2 secreted from WAT in obesity has been reported to contribute to tissue macrophage accumulation and insulin resistance by inducing a chronic inflammatory state. MCP-1 has been shown to be elevated in the fatty liver of lipoatrophic A-ZIP-Tg mice. Treatment of these mice with CCR2 antagonist has been shown to ameliorate their hyperglycaemia, hyperinsulinaemia and hepatomegaly, in conjunction with a reduction in liver inflammation. However, since CCR2 antagonist can block not only MCP-1, but also MCP-2 and MCP-3, it remains unclear whether MCP-1 secreted from liver could contribute to hyperglycaemia, hyperinsulinaemia and hepatomegaly in conjunction with liver inflammation, as well as to M1/M2 polarisation.
To address these issues, we analysed the effects of targeted disruption of MCP-1 in A-ZIP-Tg mice. In the current study, we showed for the first time that targeted disruption of MCP-1 alone in lipoatrophic diabetic A-ZIP-Tg mice ameliorated insulin resistance and hepatic steatosis, which was associated with decreased ERK-1/2 and p38MAPK phosphorylation (Fig. 6 ) and alternative M2 activation of macrophages. Although food intake was not significantly different when adjusted by body weight (ESM Table 1 ), the A-ZIP-Tg mice with MCP-1 deficiency tended to exhibit increased Ppara and exhibited significantly increased Ucp2 expression in the liver (ESM Fig. 8 ), raising the possibility that the body weight and liver weight reduction (ESM Table 2 ) were due to increased energy expenditure, and that it could also contribute to the reduction in liver triacylglycerol content. However, it has been technically extremely difficult to prepare enough A-ZIP-Tg×Mcp1 −/− mice to unequivocally prove increased energy expenditure in these mice. We would like to carry out this experiment in a future study. The amounts of tyrosine phosphorylation of IR-β and serine phosphorylation of Akt were increased in livers from A-ZIP-Tg×Mcp1 −/− mice (Fig. 7) . These data suggested that the amelioration of insulin resistance by disruption of MCP-1 in A-ZIP-Tg mice, such as increased tyrosine phosphorylation of IR-β and serine phosphorylation of Akt in liver, seemed to be related to decreased ERK-1/2 and p38MAPK activation [34] , at least in part.
Although the disruption of MCP-1 in A-ZIP-Tg mice improved insulin resistance, the gene expression of macrophage markers such as Emr1 and Cd68 in the liver were not decreased compared with those seen in A-ZIP-Tg mice (Fig. 4d,e) . It was recently reported that the induction of M2 markers in resident macrophages in the liver controls hepatic lipid metabolism [35] . In this study, the M2-specific genes Chi3l3 and Arg1 were increased in livers from A-ZIP-Tg×Mcp1 −/− mice compared with A-ZIP-Tg mice (Fig. 4f,g ). These data are consistent with the results that ATMs from obese Ccr2-deficient mice express M2 markers at levels similar to those found in lean mice [12] . However, treatment with CCR2 antagonist reduced the macrophage marker gene Cd68 mRNA and Tnf-α mRNA in the livers of A-ZIP-Tg mice [18] . These results might be derived from differences between a chronic and an acute inhibition of CCR2 or between targeted disruption of MCP-1 and simultaneous inhibition of MCP-1/MCP-2/MCP-3 by CCR2 antagonist in the liver of A-ZIP-Tg mice. Previous studies have shown that CCR2 promoted obesityinduced hepatic steatosis in db/db mice [36] , that a CCR2 antagonist (propagermanium) also reduced liver TG content in db/db mice [37] , and that another CCR2 antagonist (RS 504393) ameliorated hepatomegaly but did not decrease hepatic TG content significantly (p00.144) [18] . These results raised the possibility that inhibition of MCP-1 and/or MCP-2 and/or MCP-3 by CCR2 inhibition could be involved in the suppression of hepatic steatosis. In this study, we showed for the first time that targeted disruption of MCP-1 in A-ZIP-Tg mice by itself exhibited decreased liver TG content in the liver (Fig. 5b) , clearly indicating that MCP-1 plays an important role in the onset of hepatic steatosis in the liver in A-ZIP-Tg mice.
In conclusion, we showed for the first time that targeted disruption of MCP-1 by itself ameliorated insulin resistance and hepatic steatosis, and at the same time decreased phosphorylation of ERK-1/2 and p38 MAPK (increased tyrosine phosphorylation of IR-β and serine phosphorylation of Akt) and induced alternative M2 activation of macrophages in the fatty liver from lipoatrophic diabetic A-ZIP-Tg mice. These results suggest that MCP-1 derived from tissues other than WAT, such as fatty liver, could also play an important role in the regulation of whole body insulin sensitivity, hepatic steatosis, macrophage polarisation and phosphorylation of ERK-1/2 and p38 MAPK. The current study also suggests that modulating MCP-1 in the liver would be useful therapy for diabetes and fatty liver.
